219 related articles for article (PubMed ID: 35126305)
1. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
2. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
3. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
[TBL] [Abstract][Full Text] [Related]
4. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
5. Identification of driver genes and key pathways of prolactinoma predicts the therapeutic effect of genipin.
Zhong S; Wu B; Wang X; Sun D; Liu D; Jiang S; Ge J; Zhang Y; Liu X; Zhou X; Jin R; Chen Y
Mol Med Rep; 2019 Sep; 20(3):2712-2724. PubMed ID: 31322266
[TBL] [Abstract][Full Text] [Related]
6. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
7. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
[TBL] [Abstract][Full Text] [Related]
8. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models.
Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X
Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868
[TBL] [Abstract][Full Text] [Related]
9. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Herbert KJ; Ashton TM; Prevo R; Pirovano G; Higgins GS
Cell Death Dis; 2018 Oct; 9(11):1089. PubMed ID: 30356039
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032.
Roh E; Han Y; Reddy K; Zykova TA; Lee MH; Yao K; Bai R; Curiel-Lewandrowski C; Dong Z
Oncogene; 2020 May; 39(21):4170-4182. PubMed ID: 32277233
[TBL] [Abstract][Full Text] [Related]
11. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis.
Gao T; Hu Q; Hu X; Lei Q; Feng Z; Yu X; Peng C; Song X; He H; Xu Y; Zuo W; Zeng J; Liu Z; Yu L
Cancer Lett; 2019 Mar; 445():11-23. PubMed ID: 30590102
[TBL] [Abstract][Full Text] [Related]
12. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase.
Dougherty JD; Garcia AD; Nakano I; Livingstone M; Norris B; Polakiewicz R; Wexler EM; Sofroniew MV; Kornblum HI; Geschwind DH
J Neurosci; 2005 Nov; 25(46):10773-85. PubMed ID: 16291951
[TBL] [Abstract][Full Text] [Related]
13. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting MAPK14 showed anti-prolactinoma effect.
Ding QY; Zhang Y; Ma L; Chen YG; Wu JH; Zhang HF; Wang X
BMC Endocr Disord; 2020 Sep; 20(1):138. PubMed ID: 32894113
[TBL] [Abstract][Full Text] [Related]
15. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.
Wang MY; Lin ZR; Cao Y; Zheng LS; Peng LX; Sun R; Meng DF; Xie P; Yang JP; Cao L; Xu L; Huang BJ; Qian CN
Oncotarget; 2016 May; 7(18):26604-16. PubMed ID: 27049917
[TBL] [Abstract][Full Text] [Related]
16. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase.
Diao X; Yang D; Chen Y; Liu W
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898980
[TBL] [Abstract][Full Text] [Related]
17. Paeonol suppresses solar ultraviolet-induced skin inflammation by targeting T-LAK cell-originated protein kinase.
Xue P; Wang Y; Zeng F; Xiu R; Chen J; Guo J; Yuan P; Liu L; Xiao J; Lu H; Wu D; Pan H; Lu M; Zhu F; Shi F; Duan Q
Oncotarget; 2017 Apr; 8(16):27093-27104. PubMed ID: 28404919
[TBL] [Abstract][Full Text] [Related]
18. Identification of human prolactinoma related genes by DNA microarray.
Zhao L; Lin M; Wang S
J Cancer Res Ther; 2014; 10(3):544-8. PubMed ID: 25313736
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
[TBL] [Abstract][Full Text] [Related]
20. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]